Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
A total of 76 patients with advanced epithelial ovarian carcinoma were randomised to receive 6 months of treatment with either a combination of hexamethylmelamine, 5-fluorouracil, cisplatin and prednimustine or prednimustine alone following initial surgery. Pathologically confirmed response rates were 35% for combination chemotherapy and 28% for prednimustine, and the overall survival was identical for the two groups. Seven patients achieved a pathologically defined complete response, one of whom relapsed at 8 months; the others remain disease-free 18-36 months (median, 23 months) after presentation. The extent of initial surgery significantly affected the survival of patients receiving prednimustine but not of those receiving combination chemotherapy. Prednimustine can produce durable responses in advanced ovarian cancer using a schedule that results in negligible toxicity.
Leonard
R C
RC
Department of Clinical Oncology, Western General Hospital, Edinburgh, Scotland, UK.
Smart
G E
GE
Livingstone
J R
JR
Cornbleet
M A
MA
Kerr
G R
GR
Fletcher
S
S
Webb
J N
JN
Smyth
J F
JF
D006585:Altretamine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007813:Laparotomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011238:Prednimustine / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011897:Random Allocation
D002699:Chlorambucil; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D002945:Cisplatin; D006585:Altretamine